Listed

Fate Therapeutics Inc: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 16:05 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$15.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$51.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2022-07-01 to 2022-09-30$79.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$233.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30−$86.4mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$244.0mus-gaap:OperatingIncomeLoss
Net income3 months2022-07-01 to 2022-09-30−$83.6mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$225.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30−$0.86us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30−$2.33us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30−$0.86us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$2.33us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-3097,023,506 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-3096,692,974 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$172.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$28.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$82.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$535.3mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$749.3mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$103.9mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2022-09-30$518.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-021840. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.